Press Releases

Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015. Sue Mahony, Ph.D., senior vice president and president of Lilly Oncology and Richard Gaynor, M.D., senior vice president of product...

  The checklist, now in its ninth year, is a direct result of post-Katrina learnings ,For Sherry Martin, M.D., starting her new job at Eli Lilly and Company (NYSE: LLY) in August 2005 was stressful enough. ...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor regarding infringement of the vitamin regimen patent for Alimta® (pemetrexed for injection). ...

Twenty-two abstracts to be presented, including new analyses from ARISTOTLE and real-world data analyses evaluating the risk of major bleeding, bleeding-related hospital readmissions, hospitalization rates and healthcare costs among patients with nonvalulvar atrial fibrillation (NVAF) receiving novel oral anticoagulant...

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 adults with type 2 diabetes...

First and only concentrated mealtime insulin analog may help people with diabetes fit their treatment into their daily lives Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), the first and only concentrated mealtime insulin analog in the U.S.,...

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for Opdivo for the treatment of patients with previously untreated advanced melanoma. The...